



FemmePharma
GLOBAL HEALTHCARE, INC.

FemmePharma, Inc. Secures Round of Financing

July 7, 2003

WAYNE, PA - FemmePharma, Inc. a women's prescription pharmaceutical company, recently announced the completion of a round of financing. Wynnefield Capital Advisors, one of FemmePharma's existing investors, provided the capital. The financing will facilitate clinical development of FemmePharma's upcoming urinary incontinence product and pharmaceutical development for its fibrocystic breast disease product, as well provide working capital for the organization. Details of the raise were not disclosed.

"FemmePharma is pleased by Wynnefield's continued support. This recent investment will allow us to accelerate the development of products in our pipeline, ultimately to product launch. We aim to bring valuable products in women's healthcare to women in need of therapy; we are closer to that objective today," said Gerianne Tringali DiPiano, President & CEO of FemmePharma.

Andrea McFadden, a partner at Wynnefield Capital Advisors and a board member of FemmePharma, said, "We continue to be excited about being a part of FemmePharma's team. Women's healthcare is an emerging market, and FemmePharma has been especially intelligent in taking a product design approach that is specifically geared to a woman's physiology. We think they will prove to be uniquely positioned to develop this underserved market."

About FemmePharma

FemmePharma was founded by Gerianne Tringali-DiPiano in 1996 to target identifiable unmet needs within the estimated \$35 billion women's healthcare pharmaceutical market. The company is concluding Phase 2 clinical trials for its first drug, a new treatment for endometriosis. It is devoted to developing safe and effective drugs that minimize or eliminate unpleasant side effects associated with many drugs by designing them in a manner that is specifically suited to a woman's physiology, with an eye toward the changing needs of women throughout their lives. FemmePharma's mission is to create value by developing innovative "woman-friendly" products in identified areas of high-unmet need, low market penetration by existing therapeutic options and high commercial and clinical value. The company has a number of drugs in development based on its proprietary PARDEL™ technology.

###